{
    "title": "Revance will wait to seek backing for Botox-rival",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-5176307/Revance-wait-seek-backing-Botox-rival.html",
    "date": "2017-12-13",
    "keywords": [
        "revance",
        "browne",
        "rt002",
        "market",
        "approval",
        "botox",
        "drug",
        "week",
        "percent",
        "company",
        "divya",
        "grover",
        "treatment",
        "threat",
        "value",
        "allergan",
        "johnson",
        "executive",
        "dan",
        "interview",
        "developer",
        "industry",
        "severity",
        "news",
        "shiver",
        "owner",
        "plc",
        "development",
        "strategy",
        "popularity",
        "survival",
        "interest",
        "expectation",
        "leader",
        "revolution",
        "baby",
        "generation",
        "x",
        "dysport",
        "merz",
        "pharmas",
        "reach",
        "test",
        "something",
        "dermatologist",
        "investigator",
        "trial",
        "botulinum",
        "toxin",
        "portion",
        "acquisition",
        "competitor",
        "galderma",
        "leerink",
        "client",
        "note",
        "concern",
        "entry",
        "data",
        "duration",
        "claim",
        "spokesman",
        "mark",
        "marmur",
        "email",
        "reporting",
        "bengaluru",
        "editing",
        "graham",
        "saumyadeb",
        "chakrabarty"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}